Clinical research

Japan Cancer Oncology Drug Therapeutics Market Sales Size Offers US$ 15 Billion Opportunity With 1600 Drug In Clinical Trials

Friday, September 18, 2020 - 3:57pm

NEW DELHI, Sept. 18, 2020 /PRNewswire/ -- "Japan Cancer Drug Market, Dosage, Price & Clinical Trials Insight 2025" Report Highlights:

Key Points: 
  • NEW DELHI, Sept. 18, 2020 /PRNewswire/ -- "Japan Cancer Drug Market, Dosage, Price & Clinical Trials Insight 2025" Report Highlights:
    Japan Cancer Drug Market Opportunity: > US$ 15 Billion by 2025
    Insight on Cancer Drugs In Clinical Trials: 360 Drugs
    Ongoing Clinical Trials for Cancer Drugs: 1600 Trials
    Marketed Cancer Drug Clinical Insight by Companies & Indication: 141 Drugs
    Cancer Clinical Pipeline By Company, Indication & Phase
    Japan in the past few years have been observing influx in the record of novel oncology drugs that have been approved and getting used to treat millions of patients that are suffering from any type of cancer.
  • As per the report findings for Japan Cancer Drug Market, spending of the revenue in Japan is mostly concentrated towards the cancer types that have been prevailing badly in the country.
  • All this is estimated to impact the cancer drug market and the costs of the drug in Japan over the next decade.
  • Overall, the cancer drug market in Japan is estimated to reach numerous billion dollars in the coming years, leveraging the country to be the most dominant cancer drug market in Asia.

Japan Cancer Oncology Drug Therapeutics Market Sales Size Offers US$ 15 Billion Opportunity With 1600 Drug In Clinical Trials

Friday, September 18, 2020 - 3:59pm

NEW DELHI, Sept. 18, 2020 /PRNewswire/ -- "Japan Cancer Drug Market, Dosage, Price & Clinical Trials Insight 2025" Report Highlights:

Key Points: 
  • NEW DELHI, Sept. 18, 2020 /PRNewswire/ -- "Japan Cancer Drug Market, Dosage, Price & Clinical Trials Insight 2025" Report Highlights:
    Japan Cancer Drug Market Opportunity: > US$ 15 Billion by 2025
    Insight on Cancer Drugs In Clinical Trials: 360 Drugs
    Ongoing Clinical Trials for Cancer Drugs: 1600 Trials
    Marketed Cancer Drug Clinical Insight by Companies & Indication: 141 Drugs
    Cancer Clinical Pipeline By Company, Indication & Phase
    Japan in the past few years have been observing influx in the record of novel oncology drugs that have been approved and getting used to treat millions of patients that are suffering from any type of cancer.
  • As per the report findings for Japan Cancer Drug Market, spending of the revenue in Japan is mostly concentrated towards the cancer types that have been prevailing badly in the country.
  • All this is estimated to impact the cancer drug market and the costs of the drug in Japan over the next decade.
  • Overall, the cancer drug market in Japan is estimated to reach numerous billion dollars in the coming years, leveraging the country to be the most dominant cancer drug market in Asia.

Global Contract Research Organization (CRO) Markets, 2019-2020 & 2024: Increased Adoption of Hybrid Clinical Trials and Remote Patient Monitoring

Friday, September 18, 2020 - 2:30pm

DUBLIN, Sept. 18, 2020 /PRNewswire/ -- The "Post-Pandemic Growth Opportunity in the Global Contract Research Organization (CRO) Market" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Sept. 18, 2020 /PRNewswire/ -- The "Post-Pandemic Growth Opportunity in the Global Contract Research Organization (CRO) Market" report has been added to ResearchAndMarkets.com's offering.
  • With the increased threat of COVID-19 and world-wide lockdowns in effect, the contract research organization (CROs) market is seeing interruptions in ongoing clinical trials and delays of new trials.
  • It presents an overview and analysis of the global clinical trials and research outsourcing (CRO) market.
  • The two key market trends identified are the increased adoption of hybrid clinical trials and remote patient monitoring.

PRA Health Sciences and Deep Lens announce strategic relationship to accelerate patient recruitment for precision cancer trials

Friday, September 18, 2020 - 1:30pm

RALEIGH, N.C. and COLUMBUS, Ohio, Sept. 18, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ: PRAH) and Deep Lens, Inc., announced today a new strategic relationship to accelerate patient access and recruitment for oncology clinical trials.

Key Points: 
  • RALEIGH, N.C. and COLUMBUS, Ohio, Sept. 18, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ: PRAH) and Deep Lens, Inc., announced today a new strategic relationship to accelerate patient access and recruitment for oncology clinical trials.
  • Using Deep Lens VIPER technology, the patient identification process will be streamlined by instantly analyzing data within electronic health records, pathology systems and genomic profiles to enable matching of cancer patients with suitable clinical trials.
  • Deep Lens is a software company focused on a groundbreaking approach to faster recruitment of the best-suited cancer patients to clinical trials.
  • Growing with sponsors, providers, and strategic partners, Deep Lens challenges the status quo so that patients can get the therapies they want and deserve.

Worldwide Risk-based Monitoring Software Industry to 2026 - Featuring MasterControl, Veeva Systems & Techso Among Others - ResearchAndMarkets.com

Friday, September 18, 2020 - 1:05pm

The "Global Risk-based Monitoring Software Market Analysis 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Risk-based Monitoring Software Market Analysis 2020" report has been added to ResearchAndMarkets.com's offering.
  • The Global Risk-based Monitoring Software market is expected to reach $652.40 million by 2026 growing at a CAGR of 15.3% from 2019 to 2026.
  • Risk-based monitoring (RBM) software is a clinical trial-monitoring method that fulfills regulatory necessities.
  • It employs various tools, platforms and dashboards to identify signals, which indicate potential issues with trial conduct, safety, data integrity, compliance and enrollment.

Genentech’s Phase III EMPACTA Study Showed Actemra Reduced the Likelihood of Needing Mechanical Ventilation in Hospitalized Patients With COVID-19 Associated Pneumonia

Friday, September 18, 2020 - 6:00am

The cumulative proportion of patients who progressed to mechanical ventilation or death by day 28 was 12.2% in the Actemra arm versus 19.3% in the placebo arm.

Key Points: 
  • The cumulative proportion of patients who progressed to mechanical ventilation or death by day 28 was 12.2% in the Actemra arm versus 19.3% in the placebo arm.
  • Actemra is currently being investigated as a potential treatment for COVID-19 associated pneumonia, including in combination with an anti-viral in the Phase III REMDACTA clinical trial.
  • Results from the Phase III COVACTA trial in patients with severe COVID-19 associated pneumonia were released in July.
  • EMPACTA (Evaluating Minority Patients with Actemra) is a Phase III, randomized, double-blind, placebo-controlled multicenter study (EMPACTA, NCT04372186) to evaluate the efficacy and safety of Actemra in the treatment of hospitalized COVID-19 associated pneumonia among patients that are often underrepresented in clinical trials.

Immutep Reports Improving Results from INSIGHT-004 Trial

Friday, September 18, 2020 - 12:53am

SYDNEY, Australia, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) is pleased to report further interim data from its ongoing INSIGHT-004 Phase I clinical trial.

Key Points: 
  • SYDNEY, Australia, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) is pleased to report further interim data from its ongoing INSIGHT-004 Phase I clinical trial.
  • The data were presented at the ESMO Virtual Congress 2020 on 17 September 2020, CEST (poster ID number 1032P) by trial investigator at Institute of Clinical Cancer Research, Krankenhaus Nordwest (IKF), PD Dr. Thorsten Gtze.
  • It is being conducted under Immuteps collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer Inc., which are co-developing and co-commercialising avelumab.
  • INSIGHT-004 is the fourth arm (Stratum D) of the investigator-initiated INSIGHT trial which is conducted by IKF in Frankfurt, Germany.

ISPE Publishes ISPE Guide: Cleaning Validation Lifecycle - Applications, Methods, and Controls

Thursday, September 17, 2020 - 3:00pm

NORTH BETHESDA, Md., Sept. 17, 2020 /PRNewswire-PRWeb/ --The International Society for Pharmaceutical Engineering (ISPE) announced the release of its latest Guide, ISPE Guide: Cleaning Validation Lifecycle - Applications, Methods, and Controls .

Key Points: 
  • NORTH BETHESDA, Md., Sept. 17, 2020 /PRNewswire-PRWeb/ --The International Society for Pharmaceutical Engineering (ISPE) announced the release of its latest Guide, ISPE Guide: Cleaning Validation Lifecycle - Applications, Methods, and Controls .
  • The Guide was written by a group of experts and reviewed by regulators and practitioners in the field, delivering a comprehensive explanation and hands-on guidance for the cleaning validation lifecycle.
  • "We decided to address the topic because the expectations for cleaning validation are changing.
  • Key areas addressed in the Guide include:
    Purchase the ISPE Guide: Cleaning Validation Lifecycle - Applications, Methods, and Controls online, available at ISPE.org/Publications/Guidance-Documents , among ISPE's other detailed education resources on a variety of industry topics.

Nebulyft® Skincare Device Set to Transform the Anti-Aging Landscape

Thursday, September 17, 2020 - 2:19pm

IRVINE, Calif., Sept. 17, 2020 /PRNewswire/ --Rebeccatech LLC is proud to introduce the Nebulyft, World's 1st MicroRF anti-aging device that's truly non-intrusive.

Key Points: 
  • IRVINE, Calif., Sept. 17, 2020 /PRNewswire/ --Rebeccatech LLC is proud to introduce the Nebulyft, World's 1st MicroRF anti-aging device that's truly non-intrusive.
  • The Nebulyft skincare device utilizes the company's proprietary microRF technology to promote subcutaneous collagen tightening and regrowth.
  • Nebulyft skincare device aims to deliver professional skincare results for home users.The initial clinical trials demo that most users are able to see visible wrinkle reduction with a month.
  • For More information on the Nebulyft device, visit www.nebulyft.com and find Nebulyft on Youtube, Facebook and Instagram.

Atossa Therapeutics Receives Second Positive Interim Safety Assessment in Clinical Study of AT-301 Nasal Spray Being Developed for the Coronavirus Causing COVID

Thursday, September 17, 2020 - 2:30pm

This second group of eight participants received a single escalated dose of either AT-301A (placebo) or AT-301B (active drug).

Key Points: 
  • This second group of eight participants received a single escalated dose of either AT-301A (placebo) or AT-301B (active drug).
  • Based on rapid enrollment in the first half of the study, we expect to complete enrollment in the remainder of the study very quickly.
  • We anticipate that our AT-301 nasal spray will complement any traditional COVID-19 vaccine that may be developed, added Dr. Quay.
  • The ongoing Phase 1 study is a double-blinded, randomized, and placebo-controlled safety study of AT-301 nasal spray in 32 healthy adult subjects divided into two study groups.